Homepage > Company > Media > Pharma News > 2016 > FDA Drug Safety Communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C

FDA Drug Safety Communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C

Read also

FDA Announces New Domestic Generic Drug Fast-Track Review Program

FDA announced a new pilot program designed to provide faster reviews for domestically tested and manufactured generic drugs.

Rocket Company

Rocket ditches blood disorder gene therapy in ongoing pipeline pivot

AAVantgarde Announces FDA

AAVantgarde Announces FDA Orphan Drug Designation and UK CTA approval for AAVB-039 for the Treatment of Stargardt Disease

BriaCell to Present Bria-OTS+™

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting